Long-term Extension Study of Ligelizumab in Food Allergy

Key Inclusion Criteria:

• Signed informed consent form (ICF) and assent form (where applicable) obtained fromthe participant/legal representative before study participation. If a minorparticipant reaches the age of legal majority (as defined by local law), they mustbe re-consented at the next study visit

• Participants have completed the treatment period in any ligelizumab Phase IIIstudies in food allergy

• Participants who are willing to adhere to the study visits and procedures, includingreceiving injections (study treatment) and participating in the OL-OFC (open labeloral food challenge)

• Participants who agree to continue avoiding exposure to allergens (per core study)and any other foods they are allergic to throughout this study

• Participants who are able to safely continue into the study as judged by theinvestigator

Key Exclusion Criteria:

• Development of a severe or life-threatening episode of an allergic reaction thatrequired intubation and/or ICU admission during the core studies

• Development of a serious adverse event which is suspected to be related to the studytreatment judged by the investigator during the core study

• Development of uncontrolled asthma during the core study that could compromise thesafety of the participants judged by the investigator

• Development of clinically significant cardiovascular, neurological, and orpsychiatric conditions during the core study that could interfere with or compromisethe safety of the participants, interfere with evaluation or interpretation of thestudy results or preclude completion of the study judged by the investigator

• Participants who failed to comply with the protocol requirements and proceduresduring the core study, and in the Investigator's opinion they should not participatein this extension study

• Platelets <75,000/ul at end of treatment of the core study

Other protocol defined inclusion/exclusion criteria may apply